The long-term benefits of psilocybin therapy keep showing up in the data, and a follow-up study tracking cancer patients nearly five years after a single dose found that 60 to 80% still met criteria for a clinically meaningful antidepressant or anxiolytic response. That’s a striking durability rate for a one-session treatment, and it’s the kind of finding that’s pushed psilocybin-assisted therapy from a fringe research interest into the mainstream of psychedelic medicine. For anyone tracking the mental health implications of these results, the durability piece is what makes them genuinely new.
Researchers at NYU School of Medicine ran the original 2016 trial. They tested single-dose psilocybin combined with psychotherapy on cancer patients dealing with depression, anxiety, and the existential weight of a life-threatening diagnosis. Six and a half months after the dose, somewhere between 60 and 80% of participants reported meaningful relief from both depressive symptoms and acute anxiety. The numbers were good enough to keep the question open. Would the benefits hold years later, or fade like most short-term gains?
A 2020 paper published in the Journal of Psychopharmacology answered it. Agin-Liebes and her colleagues tracked down most of the original participants and re-evaluated them at three years and again at four and a half. The result: sustained reductions in anxiety, depression, hopelessness, demoralization, and death anxiety at both checkpoints. The full citation, worth quoting in plain language from the paper itself:
“Approximately 60 to 80% of participants continued with clinically significant antidepressant or anxiolytic responses.” (Agin-Liebes et al., J Psychopharmacol, 2020)
The clinical significance part matters. Researchers don’t use “clinically significant” loosely. It signals a change large enough to alter how a patient functions day to day, not just a wobble on a depression rating scale. That’s the threshold most psychedelic drug research aims at, and it’s the threshold the NYU cohort kept clearing across the follow-up window.
Plenty of treatments produce short-term improvement. The long-term part is where most antidepressants struggle. SSRIs typically work as long as a patient keeps taking them, and discontinuation often brings relapse, especially in patients carrying chronic symptoms of depression rather than a one-off episode. So a single psilocybin dose producing measurable benefits four and a half years later isn’t a marginal finding. It’s a structural challenge to how we think about the treatment of depression.
What stuck with participants wasn’t the dose. It was the experience itself. Most participants ranked the psilocybin session among the top five most meaningful events of their lives. Some put it ahead of their wedding or the birth of a child. That’s not how patients usually talk about a prescription medication, and it’s part of why the field is treating these results so seriously. The current thinking is that psilocybin may catalyze a shift in self-narrative that SSRIs simply don’t access, which is why the integration sessions after a dose tend to do so much of the lasting work.
The brain mechanism is still under active investigation, but the leading model centers on the default mode network. This network activates when we aren’t focused on a specific task. It runs the inner monologue, builds the ongoing story of who we are, and handles a lot of mind-wandering and self-reflection. In healthy brains, it switches on and off as needed. In people coping with poor mental health, particularly depression and anxiety, it tends to get stuck on. People ruminate. They cycle through the same self-critical narratives. They can’t quite step outside their own perspective.
Psilocybin quiets that network. Neuroimaging from psychedelic therapy research at Imperial College London has shown a substantial drop in default mode network activity during the experience, followed by a more flexible pattern of connectivity afterward. That flexibility appears to give patients a window to re-examine the narratives they’re stuck in. The psychotherapy component helps them translate that window into lasting cognitive change, which is why these psychedelic-assisted therapies are designed around a few rounds of preparation and integration rather than the dose alone. The therapeutic frame matters as much as the molecule.
NYU isn’t alone in this work. The Center for Psychedelic and Consciousness Research at Johns Hopkins University has run a parallel program, and their findings have been consistent. A 2020 JAMA Psychiatry paper from Alan Davis and the Johns Hopkins team studied psilocybin-assisted therapy for major depressive disorder in adults who weren’t dealing with terminal illness. Twenty-four participants received two dosing sessions plus supportive psychotherapy. At the four-week follow-up, 71% showed a clinically significant decrease in depressive symptoms and 54% met criteria for full remission of the condition.
A follow-up paper by Gukasyan and colleagues reported that, twelve months later, more than half of the original cohort still met criteria for remission. The endurance of these effects is becoming one of the more reproducible findings in psychedelic studies. Different teams, different patient populations, similar pattern.
A lot of the earliest work in psychedelic research focused on cancer patients because their distress was so acute and so specific. That gave clinicians a contained study population and a clear outcome measure. But the field has moved past that initial framing. Major depressive disorder, TRD (the shorthand for that hard-to-treat presentation), alcohol use disorder, and tobacco cessation are all on the active roster of trials.
For treatment-resistant depression in particular, this matters. About a third of patients with major depression don’t respond to standard SSRIs or even multiple medication switches. They’re the population most in need of an alternative, and they’re the population for whom traditional treatment options run thin. Psilocybin treatment for major depression has shown promise in this group across several Phase 2 trials, and Phase 3 results are starting to land. The replicated efficacy in that subgroup is what’s drawn the most regulator interest.
The protocol is similar across most current trials. A patient meets with a pair of therapists for several preparation sessions. They build trust, talk through intentions, and learn what to expect from the experience. On dosing day, the patient takes a moderate dose of psilocybin (usually around 25 milligrams) in a comfortable room with the therapists present. The session lasts six to eight hours. Eyeshades and music help direct attention inward.
In the days that follow, the patient meets again with the therapists for integration sessions. These are where the insights from the experience get worked into actual behavioral change. Without integration, the effects can fade. With it, the benefits seem to hold. That’s the consistent thread across the trials at NYU, Johns Hopkins, Imperial College, and the more recent multi-site Phase 2b and 3 studies of psychedelic treatment. Therapists keep the structure consistent in part because the early efficacy data was built on that exact protocol, and changing it would muddle the comparison to existing trials.
It’s worth being clear about the limits. The 4.5-year follow-up at NYU tracked a small group: fifteen of the original twenty-nine participants. That’s enough to publish, but it’s not a Phase 3 efficacy trial. The Davis 2020 paper at Johns Hopkins also had a small sample. Replication at scale is still in progress, and the efficacy numbers from larger trials may move once full Phase 3 data lands. That’s the normal arc of any clinical trial program. Early results are promising. Larger samples either confirm them or trim them back.
Psilocybin treatment also isn’t risk-free. The acute experience can be psychologically challenging, particularly for people with personal or family histories of psychotic disorders. The current consensus is that psilocybin shouldn’t be offered to anyone at elevated risk for psychosis, mania, or related conditions. The therapy structure exists in part to manage these risks, which is why supervised sessions remain the standard model in every legitimate clinical trial. Set, setting, and screening do a lot of the safety work that the molecule alone can’t do.
The FDA has granted psilocybin breakthrough therapy designation for treatment-resistant depression and for major depressive disorder. That doesn’t make it legal outside a clinical trial in the United States, but it does fast-track the regulatory review. Several states and Australia, which acted in 2023, have created early access pathways. Oregon’s Measure 109 created a regulated psilocybin services framework. Health Canada has approved limited access through the Special Access Program for end-of-life psychological distress. The legal picture is shifting faster than most people realize.
Insurance coverage is the next bottleneck. A psilocybin protocol involves multiple therapy hours, supervision through the dosing day, and integration sessions afterward. Per-patient cost estimates from the FDA reviews run several thousand dollars. Until reimbursement structures catch up, access will be limited to the well-resourced, even in states and countries where the pathway is technically open.
If a single session can produce benefits that hold at four and a half years, that reshapes the basic economics and clinical strategy of treating depression. Standard antidepressants are a recurring cost and a recurring decision for both patient and prescriber. A two-session protocol with multi-year durability is a different category. It looks more like an intervention than a maintenance medication, and it changes how a clinician thinks about long-term care.
That said, the data isn’t there yet to recommend psilocybin use outside a research setting in most jurisdictions. The cost structure of these therapies is also significant. Each protocol involves multiple therapists, long sessions, and serious infrastructure. Insurance coverage hasn’t caught up. That’s the next set of problems the field has to solve before this approach reaches the patients who need it most.
In the NYU follow-up, sustained antidepressant and anxiolytic responses showed up in 60 to 80% of participants at the four-and-a-half-year mark. The Johns Hopkins twelve-month follow-up by Gukasyan and colleagues reported continued remission in more than half of the original cohort with this disorder. Different studies, similar pattern: the effect of psilocybin can stick around for years rather than weeks.
Health Canada has approved limited access for end-of-life psychological distress and a few other narrow indications through the Special Access Program. Recreational use remains illegal. Clinical access is expanding but still constrained, and most legal psilocybin therapy today happens within a research trial rather than a standard clinical pathway.
A 2021 Carhart-Harris clinical trial in the New England Journal of Medicine compared psilocybin against escitalopram, a standard SSRI, in patients with moderate-to-severe depression. The two performed similarly on the primary outcome, but psilocybin showed faster onset of benefit and a different side effect profile. The trial wasn’t large enough to settle the question, but it was the first head-to-head comparison of its kind.
Yes. Most current clinical trial protocols use a moderate-to-high amount, usually in the range of 20 to 30 milligrams. Lower doses produce milder experiences with less consistent therapeutic effects. The high-dose protocol is what’s been studied the most, and it’s what the durable benefit data is based on. That said, microdosing research is moving forward separately and uses very different ranges.
Early trials in alcohol use disorder, tobacco cessation, and obsessive-compulsive disorder have all shown some signal. The data is thinnest in OCD and strongest in alcohol use disorder, where a 2022 trial by Bogenschutz at NYU reported a significant reduction in heavy drinking days at the eight-month follow-up. Outside of depression and end-of-life distress, the picture is still developing.
The Agin-Liebes 2020 follow-up wasn’t a flashy paper. It tracked a small group of cancer patients across nearly five years, ran them through standard depression and anxiety scales, and reported that the majority were still doing well. But that quiet finding is one of the more important data points in the entire psychedelic-assisted therapy literature. Combined with the parallel Johns Hopkins work and the ongoing Phase 3 trials, it’s the kind of result that’s pushing this whole psychedelic approach from speculation toward standard of care. The question now isn’t whether it works for the right patients. It’s how to get the access pathway built.
The study was published in the Journal of Psychopharmacology.
Follow me on Twitter. Check out David’s website or some of his other work here. David DiSalvo
